Peptimmune Inc.
This article was originally published in Start Up
Executive Summary
By intervening at the level of antigen processing and presentation, Peptimmune aims to develop drugs that downregulate the inappropriate immune response that occurs in such autoimmune disorders as multiple sclerosis and rheumatoid arthritis and to boost the response in the case of HIV and other viruses.
You may also be interested in...
New Strategies for Rheumatoid Arthritis Treatment
Traditional drugs for rheumatoid arthritis merely relieved symptoms or tried to slow disease progression at the expense of side effects and toxicities. New disease modifying drugs just coming to market and under development promise to intervene early in the inflammation cascade to prevent irreversible damage.
Wound Solutions Ltd.
Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.
Patient-Centric Devices Promise Cost-Efficient Advanced Wound Care
The treatment of chronic wounds is challenging, not only because of the underlying biology, but also because of more practical considerations: fragmentation in the care settings, the logistics of delivering products to patients, and the costs of chronic care. Next generation advanced wound care companies are engineering solutions to these problems.